IP Library › Granted Patent US 12,710,424
Granted Patent B2
US 12,710,424 · App. 18/262,316 · Granted Aug 18, 2026

Extraction process of pancrelipase and evaluation thereof

Inventors: Raja Reddy Kuppili (Thane, IN); Chintan Mineshkumar Vaywala (Ahmedabad, IN); Parva Yogeshchandra Purohit (Ahmedabad, IN); Mukesh Mahajan (Ahmedabad, IN); Sanjaykumar Vanrajbhat Talpara (Ahmedabad, IN)
Assignee: Kashiv BioSciences, LLC
G01N33/573G01N2333/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,710,424
App. No.
18/262,316
Filed
Jul 20, 2023
Granted
Aug 18, 2026
Kind
B2
Examiner
PAK, YONG D
Art Unit
1652
USPC
435/18
Abstract

The invention provided herein a pharmaceutical process used for an extraction of proteins from pancreatic sample and estimation of the extracted proteins. Moreover, the invention provides a use of suitable is selected from citrate-phosphate buffer and bicarbonate buffer capable to extract proteins from pancreatic sample. The invention further provides an analytical method to perform estimation of extracted proteins. This process provides an improved extraction method to quantify protein present in the pancreatic sample.

Claims (31)

1 . A process for an extraction of a pancreatic protein from a pancreatic protein sample, the process comprising:

a. treating the pancreatic protein sample with a buffer;

b. dissolving the pancreatic protein sample in the buffer;

c. collecting the extracted pancreatic protein,

wherein the suitable buffer is selected from citrate-phosphate buffer and bicarbonate buffer;

wherein the pancreatic protein sample comprises a pharmaceutical composition comprising:

one or more enzymes selected from lipase, protease, and amylase; and

one or more enzymes selected from Triacylglycerol lipase, Co-lipase, CEL lipase, Phospholipase A2, Trypsin, Chymotrypsin, Elastase, Carboxypeptidase A1, Carboxypeptidase B, Kallikrien glandular, and Alpha amylase.

2 . The process according to claim 1 , wherein the extraction of the pancreatic protein is improved in comparison to an extraction process performed without using a suitable buffer selected from citrate-phosphate buffer and bicarbonate buffer.

3 . The process according to claim 1 , wherein:

the citrate-phosphate buffer concentration is selected from about 10 mM to about 200 mM; or

the bicarbonate buffer concentration is selected from about 10 mM to about 200 mM.

4 . The process according to claim 3 , wherein:

the citrate-phosphate buffer concentration is selected from about 100 mM; or

the bicarbonate buffer concentration is selected from about 100 mM.

5 . The process according to claim 1 , wherein the citrate phosphate buffer has a pH from about 6.0 to about 6.5.

6 . The process according to claim 1 , wherein of the bicarbonate buffer has a pH from about 9.5 to about 10.

7 . The process according to claim 1 , wherein dissolving the pancreatic protein sample in the buffer is performed by stirring or shaking.

8 . The process according to claim 7 , wherein stirring is performed at 200 rpm to 300 rpm.

9 . The process according to claim 8 , wherein stirring is performed for about 20 minutes to about 30 minutes.

10 . The process according to claim 1 , wherein the extracted pancreatic protein is further subjected to estimation of protein performed by using BCA, SDS-PAGE, CE-SDS, SE-HPLC, or RP-HPLC.

11 . The process according to claim 1 , wherein the extracted pancreatic protein is further subjected to quantification of protein performed by using SDS-PAGE, CE-SDS, SE-HPLC, or RP-HPLC.

12 . The process according to claim 1 , wherein the process provides more than about 80% yield of pancreatic protein.

13 . The process according to claim 1 , wherein the process provides more than about 90% yield of pancreatic protein.

14 . The process according to claim 1 , wherein the process provides more than about 98% yield of pancreatic protein.

15 . The process according to claim 1 , wherein the extracted pancreatic protein comprises a protein selected from amylase, lipase and protease.

16 . The process according to claim 1 , wherein the process provides a pharmaceutically acceptable pancreatic protein mixture comprising one or more enzymes selected from amylase, lipase and protease.

17 . The process according to claim 10 , wherein the extracted pancreatic protein is further subjected to estimation of protein based on molecular weight by using CE-SDS.

18 . The process according to claim 10 , wherein the extracted pancreatic protein is further subjected to estimation of purity profile by using RP-HPLC.

19 . The process according to claim 10 , wherein the extracted pancreatic protein is further subjected to estimation of protein based on molecular weight by using SDS-PAGE.

20 . The process according to claim 10 , wherein the extracted pancreatic protein is further subjected to estimation of purity profile by using SE-HPLC.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 12, 2026
From: KUPPILI, RAJA REDDY; VAYWALA, CHINTAN MINESHKUMAR; PUROHIT, PARVA YOGESHCHANDRA; MAHAJAN, MUKESH; TALPARA, SANJAYKUMAR VANRAJBHAT
To: KASHIV BIOSCIENCES, LLC
Reel/Frame 074632/0856 →
SHORT FORM TERM LOAN INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 3, 2025
From: KASHIV BIOSCIENCES, LLC
To: ACQUIOM AGENCY SERVICES, AS COLLATERAL AGENT
Reel/Frame 071824/0222 →
SHORT FORM TERM LOAN INTELLECTUAL PROPERTY ASSIGNMENT Recorded May 1, 2025
From: KASHIV BIOSCIENCES, LLC
To: ACQUIOM AGENCY SERVICES LLC, AS COLLATERAL AGENT
Reel/Frame 071150/0372 →
Priority Claims (1)
IN 202121012561 · Mar 23, 2021 · national
Continuity (1)
Related Publication 20240077483A1 · Mar 7, 2024
References Cited (180)
US 5328834A · Ngo et al. · 1994 [cited by applicant]
US 8703126B2 · Liu et al. · 2014 [cited by applicant]
US 9291630B1 · Wezeman et al. · 2016 [cited by applicant]
US 9352035B2 · Zhou et al. · 2016 [cited by applicant]
US 9382317B2 · Manning et al. · 2016 [cited by applicant]
US 9556258B2 · Nti-Gyabaah et al. · 2017 [cited by applicant]
US 9598718B2 · Rupprechter et al. · 2017 [cited by applicant]
US 9683012B2 · Yoon et al. · 2017 [cited by applicant]
US 10034940B2 · Liu et al. · 2018 [cited by applicant]
US 10080793B2 · van't Oever et al. · 2018 [cited by applicant]
US 10618960B2 · Liu et al. · 2020 [cited by applicant]
US 12139510B2 · Narayan et al. · 2024 [cited by applicant]
US 20020114814A1 · Gray et al. · 2002 [cited by applicant]
US 20060228780A1 · Luo et al. · 2006 [cited by applicant]
US 20080064861A1 · Sun · 2008 [cited by applicant]
US 20080167450A1 · Pan · 2008 [cited by applicant]
US 20090252749A1 · Leister et al. · 2009 [cited by applicant]
US 20100129379A1 · Carpenter et al. · 2010 [cited by applicant]
US 20100278929A1 · Wei et al. · 2010 [cited by applicant]
US 20110129468A1 · Mccue et al. · 2011 [cited by applicant]
US 20120172299A1 · Schmalz et al. · 2012 [cited by applicant]
US 20120322733A1 · Shaw · 2012 [cited by applicant]
US 20130079498A1 · Gilljam et al. · 2013 [cited by applicant]
US 20130197198A1 · Sun et al. · 2013 [cited by applicant]
US 20130338344A1 · Ramasubramanyan et al. · 2013 [cited by applicant]
US 20140288272A1 · Allison et al. · 2014 [cited by applicant]
US 20140341843A1 · Barnes et al. · 2014 [cited by applicant]
US 20150284673A1 · Langer et al. · 2015 [cited by applicant]
US 20160115193A1 · Herigstad et al. · 2016 [cited by applicant]
US 20160228371A1 · Schultz et al. · 2016 [cited by applicant]
US 20170007712A1 · DeFrees et al. · 2017 [cited by applicant]
US 20170058019A1 · Felföldi et al. · 2017 [cited by applicant]
US 20170305999A1 · Leber et al. · 2017 [cited by applicant]
US 20170326069A1 · Brunner-Schwarz et al. · 2017 [cited by applicant]
US 20180037642A1 · Arakawa et al. · 2018 [cited by applicant]
US 20180208639A1 · Minter et al. · 2018 [cited by applicant]
US 20180327446A1 · Fong et al. · 2018 [cited by applicant]
US 20180333493A1 · Shenoy · 2018 [cited by applicant]
US 20180344630A1 · Igawa et al. · 2018 [cited by applicant]
US 20190062419A1 · Ramasubramanyan et al. · 2019 [cited by applicant]
US 20190256556A1 · Giese et al. · 2019 [cited by applicant]
US 20190298801A1 · Kerwin et al. · 2019 [cited by applicant]
US 20190343918A1 · Graham et al. · 2019 [cited by applicant]
US 20190353661A1 · Smith · 2019 [cited by applicant]
US 20190358323A1 · Liu et al. · 2019 [cited by applicant]
US 20200003714A1 · Gillespie et al. · 2020 [cited by applicant]
US 20200017569A9 · Leister et al. · 2020 [cited by applicant]
US 20200088749A1 · Salbato et al. · 2020 [cited by applicant]
US 20200230242A1 · Desai et al. · 2020 [cited by applicant]
US 20200283472A1 · Karur · 2020 [cited by applicant]
US 20210079422A1 · Oh et al. · 2021 [cited by applicant]
US 20210122782A1 · Eisenhuth et al. · 2021 [cited by applicant]
US 20210130396A1 · Sutter et al. · 2021 [cited by applicant]
US 20210179690A1 · Jayaraman et al. · 2021 [cited by applicant]
US 20210230250A1 · Lazar et al. · 2021 [cited by applicant]
US 20220194980A1 · Leiss et al. · 2022 [cited by applicant]
US 20220203347A1 · Wong et al. · 2022 [cited by applicant]
US 20220260521A1 · Upadhyay · 2022 [cited by applicant]
US 20220267473A1 · Weaver et al. · 2022 [cited by applicant]
US 20230124565A1 · Yang et al. · 2023 [cited by applicant]
US 20230166200A1 · Narayan et al. · 2023 [cited by applicant]
US 20230166201A1 · Narayan et al. · 2023 [cited by applicant]
US 20230167153A1 · Narayan et al. · 2023 [cited by applicant]
US 20230303621A1 · Mahajan · 2023 [cited by applicant]
US 20230340080A1 · Sharma et al. · 2023 [cited by applicant]
US 20230348530A1 · Narayan et al. · 2023 [cited by applicant]
US 20240077483A1 · Kuppili et al. · 2024 [cited by applicant]
US 20240156907A1 · Narayan et al. · 2024 [cited by applicant]
US 20240158437A1 · Narayan et al. · 2024 [cited by applicant]
US 20240254160A1 · Upadhyay et al. · 2024 [cited by applicant]
US 20240287159A1 · Sharma et al. · 2024 [cited by applicant]
US 20240317799A1 · Narayan et al. · 2024 [cited by applicant]
US 20240343758A1 · Narayan et al. · 2024 [cited by applicant]
US 20240343776A1 · Narayan et al. · 2024 [cited by applicant]
US 20240400612A1 · Narayan et al. · 2024 [cited by applicant]
US 20250011395A1 · Narayan et al. · 2025 [cited by applicant]
US 20250043027A1 · Weaver et al. · 2025 [cited by applicant]
US 20250059230A1 · Upadhyay et al. · 2025 [cited by applicant]
CA 2528906C · 2013 [cited by applicant]
CA 3072129A1 · 2019 [cited by applicant]
CN 103405756A · 2013 [cited by applicant]
CN 103667225A · 2014 [cited by applicant]
CN 106190935A · 2016 [cited by applicant]
CN 109142728A · 2019 [cited by applicant]
CN 109678969A · 2019 [cited by applicant]
EP 3620785A1 · 2020 [cited by applicant]
WO WO1998001549A2 · 1998 [cited by applicant]
WO WO2002082066A1 · 2002 [cited by applicant]
WO WO2005044856A2 · 2005 [cited by applicant]
WO WO2009058769A1 · 2009 [cited by applicant]
WO WO2010102241A1 · 2010 [cited by applicant]
WO WO2011150110A1 · 2011 [cited by applicant]
WO WO2012160032A1 · 2012 [cited by applicant]
WO WO2013071396A1 · 2013 [cited by applicant]
WO WO2013096791A1 · 2013 [cited by applicant]
WO WO2013180647A1 · 2013 [cited by applicant]
WO WO2015189832A1 · 2015 [cited by applicant]
WO WO2016009049A1 · 2016 [cited by applicant]
WO WO2017180594A1 · 2017 [cited by applicant]
WO WO2019043067A1 · 2019 [cited by applicant]
WO WO2019224842A1 · 2019 [cited by applicant]
WO WO2019224843A1 · 2019 [cited by applicant]
WO WO2021009669A2 · 2021 [cited by applicant]
WO WO2021038532A1 · 2021 [cited by applicant]
WO WO2021181417A1 · 2021 [cited by applicant]
WO WO2021220251A1 · 2021 [cited by applicant]
WO WO2021220252A1 · 2021 [cited by applicant]
WO WO2021220253A1 · 2021 [cited by applicant]
WO WO2021240458A2 · 2021 [cited by applicant]
WO WO2022195505A1 · 2022 [cited by applicant]
WO WO2022201056A1 · 2022 [cited by applicant]
WO WO2023047368A1 · 2023 [cited by applicant]
WO WO2023053030A1 · 2023 [cited by applicant]
WO WO2023053031A1 · 2023 [cited by applicant]
WO WO2023053032A1 · 2023 [cited by applicant]
WO WO2023057994A1 · 2023 [cited by applicant]
WO WO2023057995A1 · 2023 [cited by applicant]
WO WO2023112000A2 · 2023 [cited by applicant]
WO WO2023180977A1 · 2023 [cited by applicant]
English Translation of CN 103667225 retrieved on Sep. 10, 2025. [cited by examiner]
English Translation of CN 103405756 retrieved on Sep. 10, 2025. [cited by examiner]
Aasim et al., “The role of ligands on protein retention in adsorption chromatography: A surface energetics approach”, p. 618-624, Journal of Separation Science, vol. 37, Issue 6. Jan. 21, 2014. [cited by applicant]
Ahmed et al. (1992) “Biosep-SEC-S high-performance size-exclusion chromatographic columns for proteins and peptides,” Journal of Chromatography 599:25-33. [cited by applicant]
Balbino et al., “The anti-IgE mAb omalizumab induces adverse reactions by engaging Fc receptors”, J. Clin. Invest., 2020, 130(3):1330-1335. [cited by applicant]
Center for Drug Evaluation and Research et al., Product Quality Reviews 2024, FDA, pp. 1-161, https://www.accessdata.fda.gov /drugsatfda_docs/nda/2018/761075Orig 1 s000Chem R. pdf (Year: 2024). [cited by applicant]
Cohen et al., “Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes”, Drugs, Mar. 3, 2018, vol. 78, Iss. 4, pp. 463-478. (16 pages). [cited by applicant]
Friess et al., “Microarray-based identification of differentially expressed growth- and metastasis-associated genes in pancreatic cancer”, Cellular and Molecular Life Sciences, vol. 60, Jun. 2003, pp. 1180-1199. [cited by applicant]
GE Healthcare Life Sciences (2013) Multi modal Chromatography Handbook. GE Healthcare Bio-Sciences AB, Bjorkgatan 30, 751 84 Uppsala, Sweden, 2013, pp. 1-113. [cited by applicant]
Geng et al., “Inhibition of autoregulated TGFbeta signaling simultaneously enhances proliferation and differentiation of kidney epithelium and promotes repair following renal ischemia”, Am. J. Pathol., Dec. 16, 2010, vo… [cited by applicant]
Goke, et al. (1988) “Identification of Rat Pancreatic Secretory Proteins after Separation by High-Performance Liquid Chromatography,” Pancreas 3(2):199-206. [cited by applicant]
Gu et al. (2019) “Assessment of CE-based baseline disturbances using simulation and targeted experimental evaluation-impact on the purity determination of therapeutic proteins,” Analytical and Bioanalytical Chemistry 41… [cited by applicant]
Guo et al. (2019) “Exploring metabolic biomarkers and regulation pathways of acute pancreatitis using ultra-performance liquid chromatography combined with a mass spectrometry-based metabolomics strategy,” RSC Adv 9:121… [cited by applicant]
Guttman et al. (2020) “Better Separation Resolution of New Biopharmaceutical Modalities through Fine Tuning of the Temperature with CE-SOS” SCIEX, pp. 1-5. [cited by applicant]
Herniman et al., “Development of ultrahigh-performance liquid chromatography/mass spectrometry and ultrahigh-performance supercritical fluid chromatography/mass spectrometry assays to determine the concentration of Bitr… [cited by applicant]
International Search Report and Written Opinion for PCT/IB2020/056593 mailed Feb. 8, 2021 (10 pages). [cited by applicant]
International Search Report and Written Opinion for PCT/IB2020/058080 mailed Feb. 8, 2021 (12 pages). [cited by applicant]
International Search Report and Written Opinion for PCT/IB2021/053658 mailed Sep. 14, 2021 (15 pages). [cited by applicant]
International Search Report and Written Opinion for PCT/IB2021/053659 mailed Jul. 22, 2021 (9 pages). [cited by applicant]
International Search Report and Written Opinion for PCT/IB2021/053660 mailed Aug. 12, 2021 (10 pages). [cited by applicant]
International Search Report and Written Opinion for PCT/IB2021/054693 mailed Nov. 17, 2021 (7 pages). [cited by applicant]
International Search Report and Written Opinion for PCT/IB2022/052377 mailed Jun. 30, 2022 (8 pages). [cited by applicant]
International Search Report and Written Opinion for PCT/IB2022/052651 mailed Jul. 1, 2022 (11 pages). [cited by applicant]
International Search Report and Written Opinion for PCT/IB2022/059058 mailed Feb. 16, 2023 (8 pages). [cited by applicant]
International Search Report and Written Opinion for PCT/IB2022/059238 mailed Feb. 24, 2023 (12 pages). [cited by applicant]
International Search Report and Written Opinion for PCT/IB2022/059239 mailed Feb. 14, 2023 (7 pages). [cited by applicant]
International Search Report and Written Opinion for PCT/IB2022/059240 mailed Feb. 23, 2023 (13 pages). [cited by applicant]
International Search Report and Written Opinion for PCT/IB2022/059648 mailed Feburary 21, 2023 (8 pages). [cited by applicant]
International Search Report and Written Opinion for PCT/IB2022/059649 mailed Feburary 7, 2023 (8 pages). [cited by applicant]
International Search Report and Written Opinion for PCT/IB2022/062426 mailed Jun. 6, 2023 (8 pages). [cited by applicant]
International Search Report and Written Opinion for PCT/IB2023/052862 mailed Jul. 27, 2023 (8 pages). [cited by applicant]
Jing et al., “Separation of monocloncal antibody charge variants using cation exchange chromatography: Resins and separation conditions optimization”, Separation and Purification Technology, vol. 235, Mar. 18, 2020. [cited by applicant]
Khawli et al., “Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats”, Mabs, Nov.-Dec. 2010, 2(6):613-24. doi: 10.4161/mabs.2.6.13333. (12 pages). [cited by applicant]
Lacher et al. (2010) “Development, validation, and implementation of capillary gel electrophoresis as a replacement for SDSPAGE for purity analysis of IgG2,” mAbs, J. Sep. Sci. 33:218-227. [cited by applicant]
Lee et al. (2010) “Capillary Electrophoretic Separation of Poly(ethylene glycol)-Modified Granulocyte-Colony Stimulating Factor,” Arch Pharm Res 22(3)491-495. [cited by applicant]
Liu et al. (2005) “Highly efficient approach for characterizing nanometer-sized gold particles by capillary electrophoresis,” Analytica Chimica Acta 528: 249-254. [cited by applicant]
Lou et al., “Liquid-liquid phase separation causes high turbidity and pressure during low pH elution process in Protein A chromatography”, Journal of Chromatography, Jan. 28, 2017, vol. 1488, pp. 57-67. (11 pages). [cited by applicant]
Lui et al. “(2010) Recovery and purification process development for monoclonal antibody production,” mAbs 2(5):480-499. [cited by applicant]
Martias, et al. (2021) “Optimization of Sample Preparation for Metabolomics Exploration of Urine, Feces, Blood and Saliva in Humans Using Combined NMR and UHPLC-HRMS Platforms,” Molecules 26(4111) 16 pages. [cited by applicant]
Molecular Probes, Protein Molecular Weight Standards (P-6649), Jan. 13, 2001, pp. 1-2. [cited by applicant]
Padfield, et al. (1986) “Separation of Guinea-Pig Pancreatic Juice Proteins by Reversed-Phase High-Performance Liquid Chromatography,” Journal of Chroma. 369:133-141. [cited by applicant]
R&D Systems, Inc., “Recombinant Human CTLA 4 Fc Chimera | Catalog No. 7268-CT”. Product datasheet (online). Mar. 6, 2020. (2 pages). [cited by applicant]
Sanger-van de Griend et al. (2019) “CE-SOS method development, validation, and best practice—An overview,” Electrophoresis 40:2361-2374. [cited by applicant]
Shekhawat et al., “Structural similarity, characterization of Poly Ethylene Glycol linkage and identification of product related variants in biosimilar pegfilgrastim”, 1-33, Plos One Web. Mar. 13, 2019. (33 pages). [cited by applicant]
Singla et al., “Aggregation Kinetics for lgG1-Based Monoclonal Antibody Therapeutics”, AAPS J., May 2016, 18(3):689-702. doi: 10.1208/s12248-016-9887-0. (14 pages). [cited by applicant]
Sobczak et al., “RNA structure analysis assisted by capillary electrophoresis”, Nucleic Acids Research, Nov. 15, 2002, vol. 30, No. 22, e124. (8 pages). [cited by applicant]
Somerville et al. (1999) “Discrimination of granulocyte colony-stimulating factor isoforms by high-performance capillary electrophoresis,” Journal of Chromatography B, 732:81-89. [cited by applicant]
Turner et al., “Development of orthogonoal NISTmAb size heterogeneity control methods”, Analytical and Bioanalytical Chemistry, Mar. 2018, vol. 410, No. 8, pp. 2095-2110. (16 pages). [cited by applicant]
Voitl et al. (2010) “Application of mixed mode resins for the purification of antibodies,” Journal of Chromatography A 1217:5753-5760. [cited by applicant]
Yang et al. (2015) “High resolution separation of recombinant monoclonal antibodies by size-exclusion ultra-high performance liquid chromatography (SE-UHPLC),” Journal of Pharmaceutical and Biomedical Analysis 109:52-61. [cited by applicant]
Asermely et al., “Identification of a recombinant synaptobrevin-thioredoxin fusion protein by capillary zone electrophoresis using laser-induced fluorescence detection,” Journal of Chromatography B 695:67-75 (1997). [cited by applicant]
Degterev et al. (2011) “Improvement of the Degradation Profiling of Eculizumab and Omalizumab Monoclonal Antibodies by Liquid Chromatography-Mass Spectrometry,” Journal of Analytical Chemistry 76(14):1596-1609. [cited by applicant]
Ichiuhara et al. (2018) “Integrated flow-through purification for therapeutic monoclonal antibodies processing,” MABS 10(2):325-334. [cited by applicant]
Pennington et al. (2016) “Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange,” Nature Communications 7:11610:1-12. [cited by applicant]
Phenomenex: “High Performance Size Exclusion for Biomolecules,” Oct. 4, 2010 (Oct. 4, 2010), XP093277516, Retrieved from the Internet: URL:https://phenomenex.blob.core.windows.net/documents/7b9fe422-933e-48df-a189-373e2… [cited by applicant]
Protein Purification Handbook (2007) GE Healthcare, pp. 1-96 (Year: 2007). [cited by applicant]
Shen et al., “Formation of an Unprecedented Impurity during CE-SDS Analysis of a Recombinant Protein,” Pharm Res 37:228, 12 pages (2020). [cited by applicant]
Wang et al. Characterization and pre-clinical assessment of a proposed biosimilar to its originator Omalizumab, Eur. J. Pharm Sci 178(1):106292 (2022). [cited by applicant]
Weisbjerg et al. (2015) “Serial Coupling of Ion-Exchange and Size-Exclusion Chromatography to Determine Aggregation Levels in mAbs in the Presence of a Proteinaceous Excipient, Recombinant Human Serum Albumin,” Journal … [cited by applicant]
XOLAI R® (omalizumab) product insert https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/103976s52421bl.pdf 2003. [cited by applicant]
XOLAIR® (omalizumab) injection for subcutaneous use [package insert]. Accessdata.fda.gov. 2021. https:// www.accessdata.fda.gov/drugsatfda_docs/label/2021/103976s5238lbl.pdf (Year: 2021). [cited by applicant]